BACKGROUND: Bromodeoxyuridine (BrdU) cell cycle analysis using flow cytometry is of clinical interest for making treatment decisions or for predicting response and survival, through proliferation rate (labeling index or S-phase fraction) assessment or T(pot) calculation. Thymidylate synthase expression was tested in vitro, in vivo, and clinically as a prognostic factor for 5-fluorouracil (5FU) sensitivity. However, results were still controversial. Moreover, we had reported that 5FU sensitivity was related to the labeling index of untreated cell cultures. METHODS: We used six human cancer cell lines that exhibited a wide range of 5FU sensitivity. Cell cycle analysis was performed using flow cytometry monovariate propidium iodide (PI) analysis and bivariate distributions of BrdU incorporation versus DNA content. 5FU sensitivity was assayed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. RESULTS: In all cell lines, 5FU exposure resulted in a statistically significant G(1)/S accumulation. No statistically significant relationship was seen between G(0)/G(1) delay determined by monovariate analysis and 5FU sensitivity. However, 5FU sensitivity was statistically correlated to the labeling index and G(1)/S subpopulation assessed with bivariate analysis using BrdU incorporation versus DNA content. CONCLUSIONS: Cellular proliferation parameters using BrdU incorporation are more informative than PI for in vitro 5FU sensitivity. Because BrdU incorporation could be assessed clinically, it could also be informative for 5FU clinical response prediction. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND:Bromodeoxyuridine (BrdU) cell cycle analysis using flow cytometry is of clinical interest for making treatment decisions or for predicting response and survival, through proliferation rate (labeling index or S-phase fraction) assessment or T(pot) calculation. Thymidylate synthase expression was tested in vitro, in vivo, and clinically as a prognostic factor for 5-fluorouracil (5FU) sensitivity. However, results were still controversial. Moreover, we had reported that 5FU sensitivity was related to the labeling index of untreated cell cultures. METHODS: We used six humancancer cell lines that exhibited a wide range of 5FU sensitivity. Cell cycle analysis was performed using flow cytometry monovariate propidium iodide (PI) analysis and bivariate distributions of BrdU incorporation versus DNA content. 5FU sensitivity was assayed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. RESULTS: In all cell lines, 5FU exposure resulted in a statistically significant G(1)/S accumulation. No statistically significant relationship was seen between G(0)/G(1) delay determined by monovariate analysis and 5FU sensitivity. However, 5FU sensitivity was statistically correlated to the labeling index and G(1)/S subpopulation assessed with bivariate analysis using BrdU incorporation versus DNA content. CONCLUSIONS: Cellular proliferation parameters using BrdU incorporation are more informative than PI for in vitro 5FU sensitivity. Because BrdU incorporation could be assessed clinically, it could also be informative for 5FU clinical response prediction. Copyright 2002 Wiley-Liss, Inc.
Authors: Martha S Field; Elena Kamynina; David Watkins; David S Rosenblatt; Patrick J Stover Journal: Proc Natl Acad Sci U S A Date: 2014-12-29 Impact factor: 11.205
Authors: Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri Journal: J Control Release Date: 2016-03-24 Impact factor: 9.776
Authors: Russell T Sapio; Anastasiya N Nezdyur; Matthew Krevetski; Leonid Anikin; Vincent J Manna; Natalie Minkovsky; Dimitri G Pestov Journal: Sci Rep Date: 2017-08-22 Impact factor: 4.379
Authors: Zilal Kattan; Sophie Marchal; Emilie Brunner; Carole Ramacci; Agnès Leroux; Jean Louis Merlin; Lionel Domenjoud; Michel Dauça; Philippe Becuwe Journal: PLoS One Date: 2008-04-23 Impact factor: 3.240
Authors: Michael Höpfner; Andreas P Sutter; Alexander Huether; Gudrun Ahnert-Hilger; Hans Scherübl Journal: BMC Cancer Date: 2004-05-21 Impact factor: 4.430
Authors: W G E Direcks; S C Berndsen; N Proost; G J Peters; J Balzarini; M D Spreeuwenberg; A A Lammertsma; C F M Molthoff Journal: Br J Cancer Date: 2008-08-05 Impact factor: 7.640